Laboratory Of America Holdings: Tolmar Expands Research at Rosalind Franklin University
- Tolmar, Inc. establishes a new research facility at Rosalind Franklin University to enhance its specialized injectable drug development.
- The collaboration with RFU aims to foster innovation in urology and oncology, addressing critical treatment needs.
- Tolmar's expansion reflects its growth ambitions and strategic alignment with Illinois' life sciences ecosystem.
Tolmar Inc. Expands Its Research Footprint at Rosalind Franklin University
Tolmar, Inc., a specialty pharmaceutical company recognized for its pioneering long-acting injectable drug delivery systems, establishes a new research facility within the Innovation and Research Park (IRP) at Rosalind Franklin University (RFU). This strategic move not only reinforces Tolmar’s commitment to advancing its capabilities in developing specialized injectables but also positions the company to leverage the collaborative opportunities afforded by RFU’s dynamic research ecosystem. Founded in 2007, Tolmar specializes in creating advanced pharmaceutical solutions primarily targeting urology, oncology, and endocrinology, with its flagship product for treating advanced prostate cancer already available in 89 countries.
The new Illinois facility complements Tolmar’s existing operations in Colorado, enhancing its regional presence that includes executive offices and marketing teams based in Buffalo Grove, Illinois. Dr. Dave Loffredo, Tolmar's vice president of innovation, emphasizes the excitement surrounding the expansion, particularly the potential for collaborative research that the IRP fosters. The integration of Tolmar into the IRP underscores a growing trend within the life sciences sector, where partnerships between pharmaceutical companies and academic institutions can lead to accelerated innovation and product development.
The IRP spans 100,000 square feet and is home to multiple research centers, including those dedicated to cancer cell biology and immunology. Dr. Stace Porter, senior vice president of development operations at Tolmar, highlights the advantage of accessing world-class research facilities and collaborating with leading scientists in Lake County’s thriving life sciences community. Dr. Joseph DiMario, RFU Executive Vice President for Research, welcomes this collaboration, noting the potential for groundbreaking advancements in pharmaceutical research that can emerge from this partnership. As Tolmar strengthens its research capabilities, it positions itself for future growth and innovation in the competitive pharmaceutical landscape.
In addition to enhancing its research capabilities, Tolmar’s expansion at the IRP aligns with the broader trend of pharmaceutical companies increasingly partnering with academic institutions to foster innovation. The collaboration between Tolmar and RFU is poised to yield significant advancements in therapeutic solutions, particularly in urology and oncology, where the need for effective treatments remains critical.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

